Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 16/20 | 0.51 |
| ▸ | FABP7 | O15540 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464339 | 1.00 | AGTR2 (0.51) | AGTR2FABP7FABP5FKBP1AOPRD1 | |
| SCHEMBL464366 | 0.88 | AGTR2 (0.40) | AGTR2FABP7FABP5FKBP1AOPRD1 | |
| SCHEMBL16095440 | 0.87 | AGTR2 (0.48) | AGTR2FABP7FABP5 | |
| SCHEMBL21874030 | 0.87 | AGTR2 (0.48) | AGTR2FABP7FABP5 | |
| SCHEMBL21553619 | 0.87 | AGTR2 (0.48) | AGTR2FABP7FABP5 | |
| SCHEMBL31210291 | 0.87 | AGTR2 (0.48) | AGTR2FABP7FABP5 | |
| SCHEMBL5963754 | 0.87 | AGTR2 (0.48) | AGTR2FABP7FABP5 | |
| SCHEMBL24633952 | 0.86 | AGTR2 (0.41) | AGTR2FABP7FABP5 | |
| SCHEMBL31000495 | 0.86 | KMT2A (0.41) | AGTR2FABP7FABP5 | |
| SCHEMBL30064422 | 0.86 | AGTR2 (0.41) | AGTR2FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175038-B2 | Peptide mimetic ligands of polo-like kinase 1 polo box domain and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | The United States of America, as represented by the Secretary, Department of Health & Human Servic (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2012142245-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE GOVERNMENT OF THE UNITED OF AMERIA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2010132869-A2 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | GOVERNMENT OF THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142044-A1 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PLK4, PLK3 | AGTR2 4722/4885FABP7 2763/4885FABP5 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.